Quick Takeaways
- MAK Capital Fund LP filed SCHEDULE 13G for Protalix BioTherapeutics, Inc. Common Stock, $0.001 par value per share (PLX).
- Disclosed ownership: 5.8%.
- Date of event: 26 Feb 2026.
MAK Capital Fund LP - 26 Feb 2026 SCHEDULE 13G Report for Protalix BioTherapeutics, Inc. Common Stock, $0.001 par value per share (PLX)
- Filing Manager
- MAK Capital Fund LP
- Reporting Manager
- MAK Capital Fund LP
- Symbol
- PLX
- Shares outstanding
- 80,165,500 shares
- Disclosed Ownership
- 4,649,599 shares
- Ownership
- 5.8%
- Form type
- SCHEDULE 13G
- Filing time
- 04 Mar 2026, 16:40:44 UTC
- Date of event
- 26 Feb 2026
- Next filing
- 30 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"MAK Capital Fund LP disclosed 5.8% ownership in Protalix BioTherapeutics, Inc. Common Stock, $0.001 par value per share (PLX) on 26 Feb 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 04 Mar 2026, 16:40.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MAK Capital Fund LP | 5.8% | 4,649,599 | 0 | 4,649,599 | /s/ Michael A. Kaufman | Managing Member | |
| MAK CAPITAL ONE LLC | 5.8% | 4,649,599 | 0 | 4,649,599 | /s/ Michael A. Kaufman | Managing Member | |
| Kaufman Michael A | 5.8% | 4,649,599 | 0 | 4,649,599 | /s/ Michael A. Kaufman | Michael A. Kaufman |